Tanda ML, Piantanida E, Lai A, Lombardi V, Dalle Mule I, Liparulo L, Pariani N, Bartalena L (2009) Thyroid autoimmunity and environment. Horm Metab Res 41(6):436–442. https://doi.org/10.1055/s-0029-1215568

Article  CAS  PubMed  Google Scholar 

Braverman LE, Cooper D. (2012) Werner & Ingbar’s The Thyroid: A Fundamental and Clinical Text: Wolters Kluwer Health.

Fatourechi V (2012) Thyroid dermopathy and acropachy. Best Pract Res Clin Endocrinol Metab 26(4):553–565. https://doi.org/10.1016/j.beem.2011.10.001

Article  CAS  PubMed  Google Scholar 

Bartalena L, Fatourechi V (2014) Extrathyroidal manifestations of Graves’ disease: a 2014 update. J Endocrinol Invest 37(8):691–700. https://doi.org/10.1007/s40618-014-0097-2

Article  CAS  PubMed  Google Scholar 

Wiersinga WM, Poppe KG, Effraimidis G (2023) Hyperthyroidism: aetiology, pathogenesis, diagnosis, management, complications, and prognosis. Lancet Diabetes Endocrinol 11(4):282–298. https://doi.org/10.1016/s2213-8587(23)00005-0

Article  CAS  PubMed  Google Scholar 

Brito JP, Schilz S, Singh Ospina N, Rodriguez-Gutierrez R, Maraka S, Sangaralingham LR, Montori VM (2016) Antithyroid drugs-the most common treatment for Graves’ disease in the United States: A Nationwide Population-Based Study. Thyroid 26(8):1144–1145. https://doi.org/10.1089/thy.2016.0222

Article  PubMed  Google Scholar 

Brito JP, Payne S, Singh Ospina N, Rodriguez-Gutierrez R, Maraka S, Sangaralingham LR, Iñiguez-Ariza NM, Montori VM, Stan MN (2020) Patterns of use, efficacy, and safety of treatment options for patients with Graves’ disease: a nationwide population-based study. Thyroid 30(3):357–364. https://doi.org/10.1089/thy.2019.0132

Article  CAS  PubMed  Google Scholar 

El Kawkgi O (2024) Shifting paradigms in Graves’ disease management: an updated survey of clinical practice and emerging trends. Clinical Thyroidology® 36(9):322–5. https://doi.org/10.1089/ct.2024;36.322-325

Villagelin D, Cooper DS, Burch HB (2024) A 2023 International survey of clinical practice patterns in the management of Graves disease: a decade of change. J Clin Endocrinol Metab. https://doi.org/10.1210/clinem/dgae222

Article  PubMed  Google Scholar 

Laurberg P (2006) Remission of Graves’ disease during anti-thyroid drug therapy. Time to reconsider the mechanism? Eur J Endocrinol 155(6):783–6. https://doi.org/10.1530/eje.1.02295

Volpe R (2001) The immunomodulatory effects of anti-thyroid drugs are mediated via actions on thyroid cells, affecting thyrocyte-immunocyte signalling: a review. Curr Pharm Des 7(6):451–460. https://doi.org/10.2174/1381612013397898

Article  CAS  PubMed  Google Scholar 

Kim H, Lee TH, Hwang YS, Bang MA, Kim KH, Suh JM, Chung HK, Yu DY, Lee KK, Kwon OY, Ro HK, Shong M (2001) Methimazole as an antioxidant and immunomodulator in thyroid cells: mechanisms involving interferon-gamma signaling and H(2)O(2) scavenging. Mol Pharmacol 60(5):972–980. https://doi.org/10.1124/mol.60.5.972

Article  CAS  PubMed  Google Scholar 

Chabernaud ML, Lagorce JF, Ratinaud MH, Buxeraud J, Raby C (1996) Methimazole inhibits peripheral lymphocyte proliferation by inducing S-quiescent phase arrest. Int J Immunopharmacol 18(8–9):499–504. https://doi.org/10.1016/s0192-0561(96)00045-8

Article  CAS  PubMed  Google Scholar 

Pedro AB, Romaldini JH, Takei K (2011) Changes of serum cytokines in hyperthyroid Graves’ disease patients at diagnosis and during methimazole treatment. NeuroImmunoModulation 18(1):45–51. https://doi.org/10.1159/000311519

Article  CAS  PubMed  Google Scholar 

Mohlin E, Filipsson Nystrom H, Eliasson M (2014) Long-term prognosis after medical treatment of Graves’ disease in a northern Swedish population 2000–2010. Eur J Endocrinol 170(3):419–427. https://doi.org/10.1530/EJE-13-0811

Article  CAS  PubMed  Google Scholar 

Shi H, Sheng R, Hu Y, Liu X, Jiang L, Wang Z, Cui D (2020) Risk factors for the relapse of Graves’ disease treated with antithyroid drugs: a systematic review and meta-analysis. Clin Ther 42(4):662–75 e4. https://doi.org/10.1016/j.clinthera.2020.01.022

Struja T, Fehlberg H, Kutz A, Guebelin L, Degen C, Mueller B, Schuetz P (2017) Can we predict relapse in Graves’ disease? Results from a systematic review and meta-analysis. Eur J Endocrinol 176(1):87–97. https://doi.org/10.1530/EJE-16-0725

Article  CAS  PubMed  Google Scholar 

Vos XG, Endert E, Zwinderman AH, Tijssen JG, Wiersinga WM (2016) Predicting the risk of recurrence before the start of antithyroid drug therapy in patients with Graves’ hyperthyroidism. J Clin Endocrinol Metab 101(4):1381–1389. https://doi.org/10.1210/jc.2015-3644

Article  CAS  PubMed  Google Scholar 

Masiello E, Veronesi G, Gallo D, Premoli P, Bianconi E, Rosetti S, Cusini C, Sabatino J, Ippolito S, Piantanida E, Tanda ML, Chiovato L, Wiersinga WM, Bartalena L (2018) Antithyroid drug treatment for Graves’ disease: baseline predictive models of relapse after treatment for a patient-tailored management. J Endocrinol Invest 41(12):1425–1432. https://doi.org/10.1007/s40618-018-0918-9

Article  CAS  PubMed  Google Scholar 

Zuhur SS, Elbuken G, Yildiz I, Kadioglu P, Erol S, Sahin S, Kilinc F, Akbaba G, Topcu B, Altuntas Y (2019) External validation of the GREAT score in Turkish Patients with Graves’ hyperthyroidism treated with the titration regimen method of antithyroid drugs: a multicenter study. Horm Metab Res 51(10):627–633. https://doi.org/10.1055/a-0974-3991

Article  CAS  PubMed  Google Scholar 

Struja T, Kaeslin M, Boesiger F, Jutzi R, Imahorn N, Kutz A, Bernasconi L, Mundwiler E, Mueller B, Christ-Crain M, Meienberg F, Ebrahimi F, Henzen C, Fischli S, Kraenzlin M, Meier C, Schuetz P (2017) External validation of the GREAT score to predict relapse risk in Graves’ disease: results from a multicenter, retrospective study with 741 patients. Eur J Endocrinol 176(4):413–419. https://doi.org/10.1530/eje-16-0986

Article  CAS  PubMed  Google Scholar 

Nedrebo BG, Holm PI, Uhlving S, Sorheim JI, Skeie S, Eide GE, Husebye ES, Lien EA, Aanderud S (2002) Predictors of outcome and comparison of different drug regimens for the prevention of relapse in patients with Graves’ disease. Eur J Endocrinol 147(5):583–589. https://doi.org/10.1530/eje.0.1470583

Article  CAS  PubMed  Google Scholar 

Kimball LE, Kulinskaya E, Brown B, Johnston C, Farid NR (2002) Does smoking increase relapse rates in Graves’ disease? J Endocrinol Invest 25(2):152–157. https://doi.org/10.1007/bf03343979

Article  CAS  PubMed  Google Scholar 

Schleusener H, Schwander J, Fischer C, Holle R, Holl G, Badenhoop K, Hensen J, Finke R, Bogner U, Mayr WR, et al. (1989) Prospective multicentre study on the prediction of relapse after antithyroid drug treatment in patients with Graves’ disease. Acta Endocrinol (Copenh) 120(6):689–701. https://doi.org/10.1530/acta.0.1200689

Allahabadia A, Daykin J, Holder RL, Sheppard MC, Gough SC, Franklyn JA (2000) Age and gender predict the outcome of treatment for Graves’ hyperthyroidism. J Clin Endocrinol Metab 85(3):1038–1042. https://doi.org/10.1210/jcem.85.3.6430

Article  CAS  PubMed  Google Scholar 

Weng H, Tian WB, Xiao ZD, Xu L (2023) Prediction for recurrence following antithyroid drug therapy for Graves’ hyperthyroidism. Arch Endocrinol Metab 67(4):e000609. https://doi.org/10.20945/2359-3997000000609

Wang PW, Chen IY, Juo SH, Hsi E, Liu RT, Hsieh CJ (2013) Genotype and phenotype predictors of relapse of graves’ disease after antithyroid drug withdrawal. Eur Thyroid J 1(4):251–258. https://doi.org/10.1159/000342621

Article  PubMed  Google Scholar 

Laurberg P, Wallin G, Tallstedt L, Abraham-Nordling M, Lundell G, Torring O (2008) TSH-receptor autoimmunity in Graves’ disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study. Eur J Endocrinol 158(1):69–75. https://doi.org/10.1530/EJE-07-0450

Article  CAS  PubMed  Google Scholar 

Tun NN, Beckett G, Zammitt NN, Strachan MW, Seckl JR, Gibb FW (2016) Thyrotropin receptor antibody levels at diagnosis and after thionamide course predict Graves’ disease relapse. Thyroid 26(8):1004–1009. https://doi.org/10.1089/thy.2016.0017

Article  CAS  PubMed  Google Scholar 

Azizi F, Abdi H, Amouzegar A (2021) Control of Graves’ hyperthyroidism with very long-term methimazole treatment: a clinical trial. BMC Endocr Disord 21(1):16. https://doi.org/10.1186/s12902-020-00670-w

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bandai S, Okamura K, Fujikawa M, Sato K, Ikenoue H, Kitazono T (2019) The long-term follow-up of patients with thionamide-treated Graves’ hyperthyroidism. Endocr J 66(6):535–545. https://doi.org/10.1507/endocrj.EJ18-0418

Article  CAS  PubMed  Google Scholar 

Guo Z, Yu P, Liu Z, Si Y, Jin M (2013) Total thyroidectomy vs bilateral subtotal thyroidectomy in patients with Graves’ diseases: a meta-analysis of randomized clinical trials. Clin Endocrinol (Oxf) 79(5):739–46.